endangering patients,” said the FTC's Chair, Lina Khan. “Our inquiry requests information on the factors driving these shortages and scrutinises the practices of opaque drug middlemen.” ...

When President Trump signed an executive order this month to try to reduce drug prices ... together a report “re-evaluating the role of middlemen,” who have been the target of one of the ...

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices ...

PBMs act as intermediaries between insurance companies, drugmakers and pharmacies to negotiate drug prices for patients. Insurers, who often own the PBMs, work with the intermediaries as ...